Crestwood Advisors Group’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $399K | Buy |
1,776
+297
| +20% | +$74K | 0.01% | 488 |
|
|
2025
Q4 | $356K | Buy |
1,479
+348
| +31% | +$89K | 0.01% | 473 |
|
|
2025
Q3 | $310K | Buy |
1,131
+108
| +11% | +$29.5K | 0.01% | 461 |
|
|
2025
Q2 | $264K | Buy |
+1,023
| New | +$244K | ﹤0.01% | 471 |
|
|
2024
Q2 | – | Sell |
-2,026
| Closed | -$401K | – | 440 |
|
|
2024
Q1 | $401K | Sell |
2,026
-4,962
| -71% | -$909K | 0.01% | 308 |
|
|
2023
Q4 | $1.2M | Sell |
6,988
-1,497
| -18% | -$230K | 0.03% | 199 |
|
|
2023
Q3 | $1.25M | Sell |
8,485
-128,335
| -94% | -$23.2M | 0.03% | 176 |
|
|
2023
Q2 | $29.9M | Buy |
136,820
+361
| +0.3% | +$80.5K | 0.94% | 38 |
|
|
2023
Q1 | $29.9M | Sell |
136,459
-40,506
| -23% | -$8.79M | 1% | 38 |
|
|
2022
Q4 | $36.8M | Sell |
176,965
-5,758
| -3% | -$1.27M | 1.25% | 25 |
|
|
2022
Q3 | $39.9M | Buy |
182,723
+2,891
| +2% | +$658K | 1.42% | 19 |
|
|
2022
Q2 | $37.7M | Buy |
179,832
+6,226
| +4% | +$1.33M | 1.27% | 25 |
|
|
2022
Q1 | $42.1M | Buy |
173,606
+3,165
| +2% | +$766K | 1.18% | 29 |
|
|
2021
Q4 | $44.4M | Sell |
170,441
-4,521
| -3% | -$1.17M | 1.15% | 30 |
|
|
2021
Q3 | $46.1M | Buy |
174,962
+109
| +0.1% | +$29.8K | 1.31% | 24 |
|
|
2021
Q2 | $43.1M | Buy |
174,853
+99
| +0.1% | +$20.8K | 1.25% | 28 |
|
|
2021
Q1 | $33.9M | Sell |
174,754
-25,495
| -13% | -$5.11M | 1.07% | 36 |
|
|
2020
Q4 | $42.6M | Sell |
200,249
-4,501
| -2% | -$897K | 1.4% | 19 |
|
|
2020
Q3 | $35.1M | Sell |
204,750
-17,797
| -8% | -$3.29M | 1.32% | 24 |
|
|
2020
Q2 | $42.7M | Buy |
222,547
+2,614
| +1% | +$428K | 1.71% | 13 |
|
|
2020
Q1 | $32.4M | Sell |
219,933
-665
| -0.3% | -$106K | 1.61% | 13 |
|
|
2019
Q4 | $34.2M | Sell |
220,598
-3,494
| -2% | -$504K | 1.35% | 22 |
|
|
2019
Q3 | $30.3M | Buy |
224,092
+1,372
| +0.6% | +$180K | 1.33% | 24 |
|
|
2019
Q2 | $27.2M | Buy |
222,720
+1,213
| +0.5% | +$134K | 1.23% | 29 |
|
|
2019
Q1 | $23M | Buy |
221,507
+9,320
| +4% | +$962K | 1.65% | 22 |
|
|
2018
Q4 | $24.2M | Buy |
212,187
+882
| +0.4% | +$94.5K | 1.92% | 16 |
|
|
2018
Q3 | $24.4M | Sell |
211,305
-392
| -0.2% | -$42.9K | 1.71% | 19 |
|
|
2018
Q2 | $22.6M | Sell |
211,697
-707
| -0.3% | -$71.5K | 1.64% | 20 |
|
|
2018
Q1 | $20.9M | Buy |
212,404
+922
| +0.4% | +$87.1K | 1.64% | 21 |
|
|
2017
Q4 | $17.9M | Sell |
211,482
-782
| -0.4% | -$64.6K | 1.42% | 26 |
|
|
2017
Q3 | $16.3M | Buy |
212,264
+2,375
| +1% | +$182K | 1.4% | 27 |
|
|
2017
Q2 | $16.2M | Buy |
209,889
+1,946
| +0.9% | +$139K | 1.38% | 28 |
|
|
2017
Q1 | $14.5M | Buy |
207,943
+6,631
| +3% | +$458K | 1.28% | 36 |
|
|
2016
Q4 | $12.5M | Buy |
201,312
+4,471
| +2% | +$274K | 1.21% | 41 |
|
|
2016
Q3 | $12.8M | Sell |
196,841
-7,623
| -4% | -$507K | 1.53% | 33 |
|
|
2016
Q2 | $12.9M | Buy |
204,464
+1,395
| +0.7% | +$82.2K | 1.6% | 29 |
|
|
2016
Q1 | $11.7M | Buy |
203,069
+4,603
| +2% | +$261K | 1.39% | 33 |
|
|
2015
Q4 | $10.7M | Buy |
198,466
+366
| +0.2% | +$20.6K | 1.29% | 37 |
|
|
2015
Q3 | $10.1M | Buy |
198,100
+13,092
| +7% | +$705K | 1.31% | 37 |
|
|
2015
Q2 | $10.4M | Sell |
185,008
-2,152
| -1% | -$136K | 1.39% | 34 |
|
|
2015
Q1 | $13.4M | Buy |
187,160
+1,863
| +1% | +$121K | 1.91% | 24 |
|
|
2014
Q4 | $10.4M | Buy |
185,297
+4,382
| +2% | +$229K | 1.56% | 31 |
|
|
2014
Q3 | $8.91M | Sell |
180,915
-10
| -0% | -$509 | 1.4% | 36 |
|
|
2014
Q2 | $9.16M | Buy |
180,925
+5,510
| +3% | +$273K | 1.46% | 32 |
|
|
2014
Q1 | $7.84M | Buy |
+175,415
| New | +$7.88M | 1.28% | 40 |
|
Other funds holding RMD
VCM
VPM
DAM
Crestwood Advisors Group's RMD Position: Q1 2026 in Review
Crestwood Advisors Group increased its ResMed (RMD) stake by 20% in Q1 2026, buying an estimated $74K and bringing the position to 1,776 shares worth $399K. The position accounts for 0.01% of the portfolio, ranked #488.
Crestwood Advisors Group first reported a position in RMD in Q1 2014 and has held it in 45 quarters since. The position peaked at $46.1M in Q3 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Crestwood Advisors Group held 1,776 shares of ResMed worth $399K as of Q1 2026.
- Crestwood Advisors Group bought 297 ResMed shares in Q1 2026, an estimated $74K.
- ResMed made up 0.01% of Crestwood Advisors Group's portfolio in Q1 2026, its #488 holding.
- Crestwood Advisors Group first reported a position in ResMed in Q1 2014 and has held it in 45 quarters since.
- Crestwood Advisors Group's ResMed position peaked at $46.1M in Q3 2021.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Crestwood Advisors Group's 13F filing for Q1 2026, filed 5 May 2026.